Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab.

J Clin Med 2020 Feb 1;9(2). Epub 2020 Feb 1.

Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.

Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn's disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the α4β7 integrin. Since α4β7-expressing lymphocytes mainly infiltrate the left colon, we assessed whether localization of CD and UC influences vedolizumab-induced remission. One hundred and eighty-one patients (74 CD and 107 UC) receiving vedolizumab in 3 referral centers were retrospectively evaluated for clinical remission at week 14. Demographic and clinical characteristics were compared between remitters and non-responders, and multivariable multinomial analysis was performed to identify predictors of remission. Remission was achieved in 17 CD (23%) and 34 UC (32%) patients, respectively. In CD, localization of the lesions did not influence clinical remission. In UC, the remitters had more frequently a distal/left-sided colitis (21/34, 62%) as compared to the non-responders (9/47, 19%), and extensive colitis was more frequent in the non-responders (38/47, 81%) than in the remitters (13/34, 38%). The multivariable multinomial analysis showed that distal/left-sided colitis was associated with a higher probability of clinical remission while extensive colitis was inversely associated with induction of remission. Data indicate that UC patients with distal or left-sided colitis are more likely to achieve remission than patients with extensive colitis following vedolizumab treatment.

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9020385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073927PMC
February 2020

Publication Analysis

Top Keywords

clinical remission
16
extensive colitis
12
remission
9
distal/left-sided colitis
8
multivariable multinomial
8
ulcerative colitis
8
multinomial analysis
8
colitis
8
clinical
6
patients
5
localization lesions
4
lesions influence
4
patients localization
4
23% 32%
4
achieved 23%
4
32% patients
4
remission remitters
4
receiving vedolizumab
4
colitis 21/34
4
21/34 62%
4

Similar Publications